13073_2018_601_MOESM1_ESM.pdf (725.04 kB)
Additional file 1: of Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
journal contribution
posted on 2018-11-29, 05:00 authored by Elen Höglander, Silje Nord, David Wedge, Ole Lingjærde, Laxmi Silwal-Pandit, Hedda Gythfeldt, Hans Vollan, Thomas Fleischer, Marit Krohn, Ellen Schlitchting, Elin Borgen, Øystein Garred, Marit Holmen, Erik Wist, Bjørn Naume, Peter Van Loo, Anne-Lise Børresen-Dale, Olav Engebraaten, Vessela KristensenFigure S1. A. GII in untreated tumors within the two therapy arms. B. Frequency plots of genome wide aberration score for tumors at the time of diagnosis in the Combination arm (top) and the Chemotherapy arm (bottom). Figure S2. Number of patients showing an increase (green) or a decrease (red) in the clonality of copy number changes genome wide between diagnosis and 12 weeks after treatment: copy number losses in responders (A) and non-responders (B); LOH in responders (C) and non-responders (D); gains in responders (E) and non-responders (F). (PDF 725 kb)
